Lincotek has obtained 510(k) clearance (K252081) from the U.S. Food and Drug Administration (FDA) for its SportLinc Syndesmosis Device, a sterile, single-use implant engineered to stabilize syndesmotic trauma of the ankle. The clearance marks a key step for the company’s Medical Division as it positions the product for commercial deployment with orthopedic OEM partners.
“We pride ourselves on helping customers bring products to market in less than one year from the design concept to the 510k approval, keeping them ahead in an increasingly competitive industry. SportLinc has big commercial potential and will have a strong appeal to clinicians dealing with sports injuries. With FDA clearance in place, we’re now ready to provide a market-ready solution to orthopedic OEMs,” said Francesco Bucciotti, Head of Global Business and Business Development at Lincotek’s Medical Division.
A System Built for the Operating Room
The SportLinc device features an ultra-high-molecular-weight polyethylene suture between two low-profile titanium alloy buttons. The assembly arrives preloaded in a sterile inserter instrument, reducing preparation steps and supporting efficiency in both hospital and Ambulatory Surgery Center settings. The system is supplied as a complete, single-use package that includes a drill, drill guide, and tension handles, consolidating the surgical toolkit and reducing operational complexity for care teams.
The device is designed for use either alongside plate fixation or as a standalone solution, giving surgeons flexibility depending on the severity and nature of the injury. Its target indication, syndesmosis injuries, commonly known as high ankle sprains, involves damage to the ligaments connecting the tibia and fibula above the ankle joint, typically caused by forced external rotation of the foot.
SportLinc is designed to support the injured structure throughout the healing process, addressing a condition frequently encountered in sports trauma and ankle fracture cases.
An OEM Platform with Commercial Reach
Beyond its clinical application, Lincotek is positioning SportLinc as a platform for orthopedic industry partners. The device is available for private labeling and can serve as a predicate device, allowing OEM customers to accelerate regulatory pathways and shorten the timeline from concept to market entry.
“SportLinc was developed with a focus on balancing strength, flexibility, and ease of use – three elements that are essential in modern orthopedic surgery. It reflects the expertise and dedication of the Lincotek product development team in supporting orthopedic OEMs with continuously innovative solutions,” said Troy Walters, Product Development Director.
With U.S. clearance secured, Lincotek is now pursuing CE Mark certification to extend SportLinc’s reach into European markets, broadening the device’s commercial footprint and reinforcing the company’s strategy of supporting orthopedic OEMs across major regulatory jurisdictions.
The Race to Regulatory Advantage in Additive Medical Devices
FDA 510(k) clearance has become a strategic differentiator in the additive manufacturing medical space, not just a regulatory checkbox, but a commercial platform. Companies increasingly pursue clearances not only for the devices themselves, but to establish predicate status, license cleared processes to OEM partners, and compress the time-to-market for an entire ecosystem of related products.
This logic is playing out across multiple companies and anatomical segments. Spinal Elements received FDA 510(k) clearance for its Ventana A Anterior Lumbar Interbody Fusion system, a 3D printed titanium implant, announcing the clearance alongside the first clinical cases using the device as the company expanded its portfolio of additively manufactured interbody implants.
In December 2025, 3D Systems received 510(k) clearance expanding its VSP Orthopedics virtual surgical planning platform to include skeletally mature adolescents, eliminating previous restrictions that confined use to adults and enabling routine clinical adoption for adolescent orthopedic oncology and deformity cases, including osteosarcoma and trauma-related limb deformities.
Elsewhere, Carlsmed raised $100.5 million in a 2025 IPO to scale its aprevo platform, an AI-driven, 3D printed patient-specific spine implant system, with its cervical implants already carrying FDA Breakthrough Device designation and a U.S. launch planned for 2026, alongside a new CMS reimbursement approval allowing hospitals up to $21,125 in additional reimbursement per qualifying inpatient procedure.
For contract manufacturers and device OEMs alike, the 510(k) is no longer just a regulatory finish line, it is the starting point for commercial leverage. Each clearance compounds the next, and the companies accumulating that stack fastest are the ones defining what comes to market.
3D Printing Industry is inviting speakers for its 2026 Additive Manufacturing Applications (AMA) series, covering Energy, Healthcare, Automotive and Mobility, Aerospace, Space and Defense, and Software. Each online event focuses on real production deployments, qualification, and supply chain integration. Practitioners interested in contributing can complete the call for speakers form here.
To stay up to date with the latest 3D printing news, don’t forget to subscribe to the 3D Printing Industry newsletter or follow us on LinkedIn.
Explore the full Future of 3D Printing and Executive Survey series from 3D Printing Industry, featuring perspectives from CEOs, engineers, and industry leaders on the industrialization of additive manufacturing, 3D printing industry trends 2026, qualification, supply chains, and additive manufacturing industry analysis.
Featured image shows Lincotek secures FDA 510(k) clearance for SportLinc. Photo via Lincotek.
